Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.

Tuberculosis (TB) is the most deadly infectious disease globally. Although most individuals achieve a cure, a substantial portion develop multi-drug resistant TB which is exceedingly difficult to treat, and the number of effective agents is dwindling. Development of new anti-tubercular medications is imperative to combat existing drug resistance and accelerate global eradication of TB. Pretomanid (PA-824) represents one of the newest drug classes (ie, nitroimidazooxazines) approved in 2019 by the United States Food and Drug Administration as part of a multi-drug regimen (with bedaquiline and linezolid, BPaL) and recommended by the World Health Organization (WHO) to treat extensively-resistant (XR-TB) and multi-drug resistant tuberculosis (MDR-TB). Approval was granted through the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs, which accelerates approval for antimicrobial drugs used to treat life-threatening or serious infections in a limited population with unmet need. This review details the pharmacology, efficacy, and safety of this new agent and describes evidence to date for its role in the treatment of drug resistant TB including published, ongoing, and planned studies.

Background

Tuberculosis (TB) is estimated to infect 25% of the world’s population and is the most deadly infectious disease globally.1 Nearly 85% of individuals with TB achieve a cure; however, a substantial portion of individuals develop drug-resistant TB which has become increasingly difficult to treat, largely due to variant strains exhibiting resistance to multiple medications.1 Development of new anti-tubercular medications is imperative to combat existing drug-resistance and accelerate global eradication of TB.

Pretomanid (PA-824) represents one of the newest drug classes (ie, nitroimidazooxazines) approved for the treatment of TB. Pretomanid was approved by the United States Food and Drug Administration (FDA) in August 2019 as part of a multi-drug regimen (with bedaquiline and linezolid, BPaL) to treat extensively-resistant (XR-TB) and multi-drug resistant tuberculosis (MDR-TB). Approval was granted through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, which accelerates approval for antimicrobial drugs used to treat life-threatening or serious infections in a limited population with unmet need. Since that time, pretomanid has also been approved for limited use in India and granted marketing authorization by the European Medicines Agency (EMA). This review will detail the pharmacology of this new agent and describe evidence to date for its role in the treatment of drug resistant TB including published, ongoing, and planned studies.

Chemical Properties

Pretomanid represents the class of nitroimidazopyrans (NAP) which are derivatives of nitroimidazoles such as azomycin and metronidazole (Figure 1). The more immediate precursor of pretomanid is Ciba-Geigy compound CGI-17341 which was originally investigated as a radiosensitizer for chemotherapy and discovered to be mutagenic. It also demonstrated antimycobacterial activity which prompted the synthesis of several hundred bicyclic nitroimidazooxazoles (eg, delamanid) and NAPs including pretomanid that did not demonstrate mutagenicity. Readers interested in details about NAP stereochemistry are referred to the following references.2–6

Figure 1

Structural relationships between the nitroimidazoles, nitroimidazooxazoles, and nitroimidazopyrans.

Mechanism of Action

Non-Replicating Bacteria

Under anaerobic conditions, the putative mechanism of action for nitroimidazole prodrugs involves reductive “activation” within the mycobacteria to reactive nitro radical anion intermediates that are capable of interacting with cellular components and interrupting cellular respiration (Figure 2A).7 In MTb, NAP reduction is mediated by the bacterial deazaflavin-dependent nitroreductase (Ddn).8 Ddn relies on the reduced form of cofactor F420 (ie F420H2), as an electron donor. F420H2 is generated during the oxidation of glucose-6-phosphate to 6-phosphogluconate which is mediated by F420-dependent glucose-6-phosphate dehydrogenase (Fgd). Contributing to the biosynthesis of F420 are the proteins fbiA, fbiB, fbiC, and fbiD (Figure 2A).

Figure 2

(A) Intracellular activation pathway for nitroimidazoles. (B) Keto mycolic acid synthesis pathway. Pretomanid blocks formation of keto mycolic acids, a component of the cell wall, by impairing oxidation of precursor, hydroxymycolic acid.

Subsequent protonation of pretomanid can also generate desnitro metabolites and nitrous acid which further decompose to nitric oxide. One investigation demonstrated that cellular nitric oxide production increases in a dose-dependent manner following anaerobic co-incubation of M. bovis cultures with pretomanid.8 It should be noted that only the lowest pretomanid concentrations evaluated in this study reflect those that can reasonably be expected in the plasma at steady-state following administration of the approved 200 mg once daily dose. Consequently, the contribution of nitric oxide release to efficacy in mycobacterial lesions and infected immune cells remains to be confirmed. However, preclinical rat disposition data do suggest that autoradiographic signals in lung 4 hours after oral administration of [14C]pretomanid are approximately 50% higher than observed in blood.9

Replicating Bacteria

Pretomanid demonstrates the ability to inhibit protein and lipid biosynthesis under conditions where nucleic acid synthesis remains unaffected.2 One proposed mechanism suggests that pretomanid reduces the availability of keto mycolic acids, components of the cell wall lipid bilayer, by impairing oxidative transformation of precursor hydroxymycolates (Figure 2B).2,10 Whether this reflects direct action on the deazaflavin cofactor F420-dependent hydroxymycolic acid dehydrogenase (fHMAD)11 or indirect action upstream of this enzyme is unclear from these reports.

A more recent study examining MTb metabolomic signatures mid-log phase suggests that pretomanid targets the pentose phosphate pathway resulting in the accumulation of phosphate sugars.12 This leads to the toxic accumulation of methylglyoxal, a highly reactive ketoaldehyde that glycates nucleic acids and proteins prompting cellular arrest.12,13 Given the redox relationship between Ddn and Fgd illustrated in Figure 2A, this proposed mechanism may impact latent bacteria as well as replicating bacteria. Notably, this study confirms a mechanism of action wholly distinct from other agents used to treat MTb including ampicillin, ethambutol, ethionamide, isoniazid, kanamycin, linezolid, rifampin, and streptomycin.12

Mechanisms of Resistance

Nitroimidazopyran-resistant mutants do not efficiently reduce nitroaromatic compounds and do not appear to generate the polar reactive metabolites of pretomanid.2 For mutants selected in vitro, this inability to activate pretomanid has been linked to sequence variations in the same genes responsible for its activity, namely those encoding Ddn, Fgd, and the proteins involved in F420 biosynthesis (fbiA, fbiB, fbiC) (Figure 2A).14–17 Resistance explained by sequence variations in these 5 genes accounted for 83% of the isolates examined in one study (Ddn 29%, Fgd 7%, fbiA 19%, fbiB 2%, fbiC 26%). The remaining 17% of isolates demonstrated no identifiable sequence variations in these genes, suggesting the presence of additional loci that mediate resistance.14

A more recent study may elucidate the missing mechanism(s). An investigation of spontaneous mutants isolated in vivo from a murine model attributed pretomanid resistance in 90% of isolates to the same 5 genes noted previously, with a similar rank order (Ddn 12%, Fgd 4%, fbiA 15%, fbiB 4%, fbiC 55%). In the remaining 10% of isolates, the authors were able to attribute resistance to sequence variations in what they identified as CofC (RV2983). Wild-type Rv2983 paired with a variant RV2983 restored pretomanid susceptibility. Notably, CofC appears to be the archaeal homolog of bacterial fbiD18 and thus may also be involved in F420 biosynthesis.19

Though genes involved with the F420-dependent pathway play a role in managing oxidative stress, with limited exception, they are not represented among those that appear to be required for the growth and survival of MTb.20–24 Functional or structural analogs of these proteins contribute to redundancy in this organism rendering little loss in mycobacterial fitness despite disruption of the genes. Accordingly, mutations easily arise under selection pressure explaining the diversity of sequence variations that have been observed in resistant mutants.14,19,25 The exceptions are fbiC, where knockout mutants are found to be hypersusceptible to oxidative stress generated by selected naphthoquinones,26 and Ddn mutants where inactivation seems to affect the resuscitation of dormant bacilli.25

Recent data also illustrate the importance of monitoring resistance to other agents in the approved regimen. The rplC gene encodes ribosomal protein L3 which is involved with antimicrobial binding,27 and rplC variants have been reported to confer resistance to oxazolidinone (eg, linezolid).28 In a recent study of induced dual resistant (Iinezolid and pretomanid) MTB strains, variants in the rplC gene occurred with high frequency (≥ 86%) and were more virulent in mice.27 Monitoring for the emergence of resistance with clinical use of the BPaL regimen will be essential.

Emergence of Resistance

Several studies have examined the frequency of spontaneous resistance to pretomanid in vitro (TB Alliance, personal communication data).2,14,29 The data suggest a mutation frequency (10−5 to 10−7) greater than that of rifampin but comparable to other agents including isoniazid, ethambutol, and pyrazinamide.30 Spontaneous mutation rates appear to be influenced by the concentration of pretomanid to which the isolates are exposed and the starting mycobacterial inoculum. Considering putative mycobacterial loads at time of diagnosis and consistent with the traditional approach to MTb treatment, pretomanid should be used in combination with other anti-mycobacterial agents.

The emergence of pretomanid resistance in treatment has also been described in animal models,31,32 but data on frequencies are limited. In BALB/c and C3HeB/FeJ mice infected with MTb H37Rv via aerosol, investigators observed a dose-dependent increase in spontaneous pretomanid-resistance.19 The spontaneous frequency of resistant mutants could not be estimated in untreated C3HeB/FeJ mice because they succumbed early. However, BALB/c mice demonstrated spontaneous resistance, in the absence of pretomanid exposure, at a rate of ~10−5 and the fraction of total CFU constituted by pretomanid-resistant isolates increased in direct proportion with dose up to 300 mg/kg.19 In a second study of 4- to 6-week-old female BALB/c mice infected with MTb (strain H37Rv, MIC 0.125 μg/mL), the proportion of CFU resistant to pretomanid monotherapy after 2 months of treatment (100 mg/kg) was 3.8×10−3.33 In combination with INH, the proportion of CFU resistant to pretomanid dropped to 5.0×10−6.33 These data similarly highlight the potential for selective amplification of pretomanid resistance. However, the sponsor reported no emergence of resistance in the human EBA studies (albeit with methodologic limitations) (TB Alliance, personal communication data).

With respect to cross resistance, the sponsor examined susceptibility profiles for 9 pretomanid resistant MTb H37Rv strains (MGIT MIC > 16 μg/mL); 6 isolated from the lungs of infected mice that had been treated with pretomanid and 3 spontaneous mutants selected on pretomanid-containing plates. Their study revealed that 8 of the 9 strains were found to be resistant to delamanid and 1 strain each was resistant to kanamycin and pyrazinamide. All 9 isolates remained susceptible to amikacin, bedaquiline, capreomycin, clofazimine, ethambutol, ethionamide, isoniazid, linezolid, moxifloxacin, ofloxacin, rifampin, and streptomycin (TB Alliance, personal communication data). Among 22 MDR and extremely drug resistant (XDR) MTb isolates originating from the Tuberculosis Biobank at the National Clinical Laboratory on Tuberculosis (Beijing, China), 5 of 7 delamanid-resistant isolates (MIC ≥16) were susceptible to pretomanid (MIC 0.016 to 0.063 mg/L).16 An additional 2 pretomanid-resistant isolates were susceptible to delamanid. Pretomanid activity was also evaluated in MTb H37Rv isolates, resistant to the more recently discovered nitrofuranylamides (NFAs) and 5-nitrothiophenes (5NP) which share structural features with pretomanid and delamanid. Of 25 NFA-resistant isolates, 8 were cross resistant to pretomanid, 11 were resistant to delamanid, and 7 were resistant to both suggesting incomplete cross resistance between these structurally similar compounds.34 All 11 of the 5NP-resistant isolates were fully cross-resistant to pretomanid.35

Spectrum of Activity

Mycobacterium tuberculosis

Under routine culture conditions, minimum inhibitory concentrations (MIC) for pretomanid against drug-susceptible (DS), monoresistant, MDR, and XDR isolates of MTb range from 0.005–0.48 μg/mL (TB Alliance, personal communication data). These data suggest that resistance phenotype has limited impact on pretomanid activity. MICs increase approximately 3- to 4-fold in the presence of 4% human albumin and more than 6-fold in the presence of 50% human serum.36,37 Minimum bactericidal concentrations (MBC) against MTb H37Rv under aerobic conditions (0.02 μg/mL) are approximately twice that of the MIC (0.01 μg/mL) while non-replicating mycobacteria in low-oxygen conditions demonstrate an MBC (6.3 μg/mL) approximately 7.5-fold higher than the MIC (0.82 μg/mL) (TB Alliance, personal communication data).

Non-MTb Species

Pretomanid demonstrates activity against other species in the Mycobacterium tuberculosis complex (MTBC) including M. bovis, M. africanum, and M. pinnipedii (MIC range <0.0312 to 0.125 μg/mL). Activity against M. ulcerans (≤4 to ≥16 μg/mL) and M. canettii (8 μg/mL) is reduced while no activity is seen against M. phlei, M. smegmatis, M. fortuitum, M. smegmatis, M. leprae and M. avium complex (TB Alliance, personal communication data).38 Activity against M. kansasii may be reduced (8 µg/mL) or non-existent (TB Alliance, personal communication data).38 When examined for activity against commonly encountered non-mycobacterial species, pretomanid demonstrated no appreciable activity against Streptococcus pneumoniae, S. pyogenes, S. mutans, Staphylococcus aureus, S. epidermidis, Enterococcus faecalis, E. faecium, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Enterobacter cloacae (MIC >128 μg/mL). Activity against Candida albicans was also absent (MIC >50 μg/mL) (TB Alliance, personal communication data).

When tested on a panel of anaerobic bacterial species including gram-positive, gram-negative and microaerophilic, pretamonid was largely ineffective with MIC ranging from 2 to >32.39 Pretamonid, and the structurally similar metronidazole, were similarly ineffective against H. pylori in this in vitro panel. Given that metronidazole is an effective clinical tool against anaerobic infections, these data should be interpreted with caution. Pretomanid activity (MIC) against the various species were as follows: C. difficile (2 ug/mL), L. acidophilus (>32 µg/mL), G. vaginalis (>32 µg/mL), P. micros (<32 µg/mL), P. asaccharolytica (2 µg/mL), P. acnes (>32 µg/mL), B.fragilis (16 µg/mL), B. longum (>32 µg/mL), F. nucleatum (4 µg/mL), M. mulieris (>32 µg/mL), P. bivia (32 µg/mL), V. parvula (>32 µg/mL), H. pylori (16 µg/mL).

Pre-Clinical Activity

The intracellular activity of pretomanid against MTb (6.42 log10 CFU) has been investigated in macrophages differentiated from human THP-1 monocytes. Following 4 hours of drug exposure and an additional 68-hours of culture, viable bacterial counts revealed that the intracellular potency of pretomanid appears comparable to isoniazid (INH) and inferior to delamanid and rifampin by 3-fold and 2-fold, respectively.40 Though intracellular: extracellular ratios vary by drug and incubation condition, average extracellular (peak plasma) concentrations (µg/mL) are 0.2–0.6 (delamanid), 5–15 (rifampin), 1.1–2.2 (pretomanid), and 3–10 (isoniazid).41–43

In animal models, initial investigations into relative NAP activity against a luminescent strain of MTb H37Rv illustrated that pretomanid is as active as metronidazole and more active than its predecessor CGI 17341 or isoniazid against static MTb.2 Early studies also examined the activity of pretomanid in a BALB/c murine model where the same luminescent strain of MTb H37Rv was injected by tail vein. These data offer evidence of a dose-response relationship and allude to potency that is comparable to INH.2 Subsequent dose ranging studies (3.125 to 200 mg/kg) in a BALB/c murine aerosol model set out to establish the minimum effective dose (MED), defined as the lowest dose capable of preventing the development of gross lesions in the lung and spleen, and the minimum bactericidal dose (MBD), defined as the lowest dose that reduces lung CFU by 99%. In mice these were determined to be 12.5 mg/kg and 100 mg/kg, respectively.33 Independent rapid in vivo screens confirmed ≥ 2 log10 CFU reductions in the lungs of both gamma interferon knockout mice and immunocompetent C57BL/6 mice at a dose of 100 mg/kg.44 Long-term in vivo screens further demonstrated that at 100 mg/kg, pretomanid reduces the CFU in lungs and spleens of C57BL/6 mice to the same extent as INH (25 mg/kg), gatifloxacin (100 mg/kg) and moxifloxacin (100 mg/kg). At lower doses, pretomanid (50 mg/kg), INH (10 mg/kg), and rifampin (10 mg/kg) each demonstrated comparable and persistent reductions in CFU over a 4 month treatment window; however, 3 months post-treatment all mice receiving pretomanid or INH relapsed, indicating a failure to achieve sterile cure as a single agent.45 A combination regimen including pretomanid (at 50 or 100 mg/kg) with bedaquiline and an oxazolidinone (sutezolid or linezolid) led to CFU reductions a full order of magnitude lower than can be achieved with pretomanid alone, and complete or near complete sterilization was observed in some cases (TB Alliance, personal communication data).46,47

Initial estimates of pretomanid (40 mg/kg) activity in the guinea pig model closely paralleled those observed in early mouse models showing near equivalent reduction in mycobacterium burden in the spleen and lung compared with isoniazid (25 mg/kg).2 One additional investigation examined various drugs alone and in combination in the guinea pig model.48 In this study, distinctions between 3-drug regimens (vs dual or monotherapy) could be appreciated with the combination pretomanid, moxifloxacin, and pyrazinamide (PaMZ) demonstrating significantly greater reductions in CFU compared with rifampin, isoniazid, pyrazinamide (RHZ); however, by 2 months both groups were culture negative. Among 2-drug regimens no clear distinctions were observed.48

In an attempt to understand the relationship between pretomanid exposure and response, time-kill kinetics of pretomanid against MTb H37Rv under aerobic conditions were evaluated at concentrations ranging from 0.12 to 2.0 μg/mL (TB Alliance, personal communication data). Based on these experiments, pretomanid appears to exhibit both concentration- and time-dependent bactericidal activity. Though only 2 concentrations were tested under anaerobic conditions (3 and 12.5 μg/mL), a similar observation was noted (TB Alliance, personal communication data). Dose fractionation studies were also conducted in BALB/c mouse models.49 These studies attempted to disassociate interdependent pharmacokinetic surrogates [ie, maximum concentration to MIC ratio (Cmax/MIC), area-under-the-curve to MIC ratio (AUC/MIC), and percent of time spent above the MIC (%T>MIC)] so as to identify the measure most closely associated with bactericidal activity. In total, 31 different pretomanid dosing regimens were examined. Among the surrogates evaluated, %T>MIC demonstrated the strongest association with CFU counts in the lung (r2= 0.87), followed by AUC/MIC (r2= 0.60). Only a weak association was observed with Cmax/MIC (r2= 0.17).49 Using these models and pharmacokinetic data from Phase I studies, the investigators ran simulations exploring putative %T>MIC values for pretomanid at MICs ranging from 0.03125 to 0.25 μg/mL. At the labeled 200 mg dose, pretomanid concentrations are predicted to spend over two-thirds of the dosing interval above the MIC50. Modeling and simulation have also been used to explore the efficacy of pretomanid-containing regimens other than the FDA-approved BPaL. Pretomanid plus moxifloxacin appeared effective at eliminating MTB burden in vitro.50,51 In a recent exposure-response model-based meta-analysis in mice, the addition of pretomanid to rifampicin and bedaquiline reduced the simulated bacterial activity of bedaquiline in multi-drug regimens; however, predicted MICs were still within the range of susceptibility.52

Clinical Microbiology

Four clinical studies evaluated the early bactericidal activity (EBA) of pretomanid in humans after 14 days of dosing demonstrating that pretomanid was non-inferior to an isoniazid, rifampin, pyrazinamide, ethambutol (HRZE) containing regimen (Table 1). Two additional studies examined the EBA of pretomanid containing regimens after 8 weeks of dosing and suggested that these outperformed HRZE at 8 weeks (Table 1). Notably, none of the regimens evaluated reflect the FDA approved BPaL regimen. It should be noted that the data provided in the table reflect those submitted as part of the NDA and the numbers are not entirely consistent with the data presented on the ClinicalTrials.gov website or in the related study publications.53–56 Per the sponsor, these discrepancies are due to a change in the method used for calculating EBA [personal communication K. Schostack]. The trends in the data remain unchanged and the conclusions drawn are largely unaffected. Recent modeling and simulation studies using data from these early phase clinical trials (eg, NC-002, NC-005, NC-006, Nix-TB) suggest that the approved pretomanid dosing regimen (200 mg daily with food) provides optimal exposure (eg, %T>MIC) compared with alternate dosing schemes to meet efficacy endpoints even after assuming wide inter-individual variability in drug disposition.57,58

Table 1

Clinical Studies Evaluating Early Bactericidal Activity (EBA) of Pretomanid in Humans

Study	Resistance	Regimen	n	Rate of Change in Sputum
(Objective)	Phenotype			CFU	TTP
CL-010 (14d EBA)	DS-TB	Pa50	15	0.060 (0.069)	2.78 (2.73)
		Pa100	15	0.099 (0.069)	5.82 (3.08)
		Pa150	15	0.106 (0.085)	4.55 (3.76)
		Pa200	16	0.111 (0.074)	5.10 (3.25)
		HRZEBW	8	0.141 (0.054)	11.10 (4.78)
CL-007 (14d EBA)	DS-TB	Pa200	15	0.121 (0.067)	3.61 (3.09)
		Pa600	15	0.119 (0.044)	4.45 (3.16)
		Pa1000	16	0.106 (0.089)	5.94 (3.84)
		Pa1200	15	0.127 (0.084)	5.82 (3.39)
		HRZEBW	8	0.133 (0.061)	9.71 (4.76)
NC-001 (14d EBA)	DS-TB	Pa200 M400 ZBW	15	0.233 (0.128)	18.48 (22.58)
		Pa200 ZBW	15	0.153 (0.040)	8.81 (3.47)
		B700>400 Pa200	15	0.114 (0.050)	5.86 (2.79)
		B700>400 ZBW	15	0.134 (0.102)	9.97 (6.99)
		B700>400	15	0.065 (0.068)	5.41 (3.52)
		HRZEBW	10	0.140 (0.094)	11.84 (3.93)
NC-003 (14d EBA)	DS-TB	B400>200 Pa200 Z1500 C300>100	15	0.111 [0.037,0.184]	0.026 [0.017,0.035]
		B400>200 Pa200 Z1500	15	0.167 [0.078,0.256]	0.029 [0.017,0.035]
		B400>200 Pa200 C300>100	15	0.076 [0.007,0.147]	0.017 [0.010, 0.023]
		B400>200 Z1500 C300>100	15	0.119 [0.031,0.211]	0.021 [0.014, 0.030]
		Z1500	15	0.037 [−0.025,0.100]	0.008 [0.003, 0.014]
		C300>100	15	0.017 [−0.086,0.055]	−0.001 [−0.006, 0.005]
		HRZEBW	15	0.151 [0.070,0.231]	0.027 [0.021, 0.032]
NC-002 (8 wk trial)	DS-TB or MDR-TB	Pa100 M400 Z1500	60	0.133 [0.109,0.155]	0.020 [0.015,0.025]
		Pa200 M400 Z1500	62	0.155* [0.133,0.178]	0.020 [0.016,0.024]
		HRZEBW	59	0.112 [0.093,0.131]	0.017 [0.013,0.021]
		Pa200 M400 Z1500	26	0.117 [0.070,0.174]	0.015 [−0.001,0.031]
NC-005 (8 wk trial)	DS-TB or MDR-TB	B200 Pa200 Z1500	60	0.109 [0.097,0.121]	5.17* [4.61,5.77]
		B400>200 Pa200 Z1500	59	0.123 [0.109,0.139]	4.87* [4.31,5.47]
		HRZEBW	61	0.116 [0.106,0.127]	4.04 [3.67,4.42]
		B200 Pa200 M400 Z1500	60	0.156* [0.125,0.198]	5.18* [4.60,5.83]

Notes: Data are presented as mean (SD) [CI]. B700>400700 mg day 1, 500 mg day 2, 400 mg days 3–14; B400>200 either 400 mg day 1, 300 mg day 2, 200 mg days 3–14 (NC-003) or 400 mg days 1–14, 200 mg days 15–56 (NC-005); C300>100300 mg day 1–3, 100 mg days 4–14. *Statistically different from HRZE.

Abbreviations: Pa, pretomanid; B, bedaquiline; M, moxifloxacin; Z, pyrazinamide; C, clofazimine; H, isoniazid; R, rifampicin; E, ethambutol.

Pharmacology and Toxicology

The physicochemical properties of pretomanid are an important determinant of its pharmacologic and toxicologic effects. Pretomanid is a highly lipophilic compound with low solubility.59 Based on the partition coefficient, pretomanid is predicted to diffuse across lipid membranes with minimal difficulty.

Absorption

The absolute bioavailability is suggested to be less than 50% based on oral and IV administration in male cynomolgus monkeys. Cmax demonstrates wide interindividual variability (%CV 127) in healthy volunteers60 with Tmax at 4–5 hours. After a single oral dose of 50–750 mg given to healthy volunteers, systemic exposure increased to approximately 55–80% of what would be expected if truly dose proportional. A plateau in systemic exposure was seen after single doses ≥1000 mg. After multiple doses, pretomanid displayed an accumulation factor of ~2. Tmax remained 4–5 hours across single or multiple doses.61

Two randomized, cross-over studies have been conducted in healthy volunteers to assess the effect of food on the pharmacokinetics of pretomanid. In contrast to non-human primates, humans have markedly higher exposures to pretomanid if administered in the fed state compared with the fasted state. In the first study, a 1000 mg dose was explored administered as 5×200 mg tablets. In the second study, 50 mg and 200 mg doses were examined each administered as an individual 50 mg or 200 mg tablet.62 Pretomanid was administered after a 10-hour fast or a high-calorie, high-fat meal with an 8-day washout between doses. At every dose (50, 200, 1000 mg), pretomanid exposures were elevated when co-administered with a high-fat meal. The relative increase in bioavailability gets disproportionately larger with increasing dose, likely accounted for by an overall reduction in bioavailability (less than proportional increase in exposure) at higher doses in the fasted state. Only nominal changes in Tmax and half-life were observed. Thus, at the labeled dose of 200 mg, average increases of 76% in Cmax and 88% in AUC can be expected. A recent study suggests that this increased exposure in the fed state may be leveraged to negate the reduction expected with co-administration of rifampin.63

Distribution

Pretomanid is distributed throughout the body (Vd/F 92–180 L) (TB Alliance, personal communication data)64 and enters the central nervous system.65 Pretomanid is moderately protein bound in human plasma, mainly to albumin, ranging from 86.3 to 86.5%.66 The ratio of pretomanid in blood to plasma was examined in two studies and found to be less than 1, suggesting a low potential for partitioning into red blood cells. Across three concentrations (2.5–10 µg/mL), ratios ranged from 0.66–0.83 Kb/p and 0.31–0.68 Ke/p.66

Metabolism

Pretomanid undergoes phase I and phase II biotransformation by multiple metabolic pathways (eg, oxidation, nitro reduction, oxidative deamination, oxidative cleavage, glycine conjugation, glucuronidation66) resulting in numerous metabolites. The most abundant metabolite identified in primary human hepatocytes is the trifluoromethoxy-benzoic acid glycine conjugate; however, very little drug was transformed in this in vitro study (5–8%) as compared with the extensive biotransformation seen in humans (<1% unchanged in urine).

Among the cytochromes P450 (CYP), CYP3A4 appears to account for up to 20% of pretomanid biotransformation, a contribution that is abolished in the presence of the strong CYP3A4 inhibitor, ketoconazole. Other microsomal enzymes may contribute to pretomanid metabolism, although studies in recombinant enzymes suggest that CYP2C9, CYP2C19, and CYP2D6 play a negligible role.66 Clearance may be saturable at high concentrations above those expected with labeled dosing (>600 mg/daily),60 and no data are yet available for individuals with impaired liver function, though that study is forthcoming as requested by the FDA.

With respect to drug-drug interaction potential, the ability of pretomanid to inhibit phase I metabolic pathways, directly and in a time-dependent manner, has been investigated. In vitro, pretomanid demonstrates the potential to directly inhibit CYP3A4/5 up to 91%66 at concentrations in excess of those observed with routine dosing. A downward shift in IC50 under time-dependent conditions is seen for several drug-metabolizing enzymes and suggests a potential for CYP3A, CYP2C8, and CYP2C19 mediated drug-drug interactions. In contrast, the recorded IC50 values for CYP1A2 and CYP2D6 (>100 μM) suggest that no clinically significant inhibition is expected for their substrates. The potential for pretomanid to induce phase I DME was also evaluated in primary human hepatocytes from 4 individual donors. CYP3A4 and CYP2C9 induction appears to be negligible at clinically relevant concentrations. The large degree of variability for CYP2E1 makes the findings inconclusive. CYP2D6, CYP2A6, and CYP2C19 have not been tested.66

A limited number of healthy volunteer studies are available exploring the in vivo impact of the potential for these drug-drug interactions identified in vitro. One study details the impact of CYP3A inducers (efavirenz, lopinavir/ritonavir, rifampin) on the disposition of pretomanid67 and two studies examined the impact of pretomanid on CYP3A4 substrates (midazolam, efavirenz, lopinavir/ritonavir).67,68 In healthy volunteers, coadministration of pretomanid with the CYP3A4 inducer rifampin reduces pretomanid exposure by over 50%. The CYP3A4 inducer efavirenz reduces pretomanid exposures by ~30% whereas exposures drop by less than 20% when co-administered with the weak inducer lopinavir/ritonavir. When the impact of pretomanid is measured on co-administered CYP3A substrates, there is no appreciable effect on efavirenz or lopinavir/ritonavir. At a dose twice that recommended by the FDA, modest induction of midazolam is observed as evidenced by both a reduction in the parent compound and an increase in the formation of its CYP3A mediated metabolite, 1ʹ-hydroxy midazolam. The clinical impact of this observation is likely limited and the FDA concludes that pretomanid can be administered with other CYP3A substrates. However, co-administration should be avoided with rifampin, efavirenz, or other moderate to strong inducers of CYP3A4.

Two additional studies in rats examined the disposition of pretomanid, moxifloxacin, pyrazinamide, and darunavir alone and in combination.69,70 Darunavir demonstrates strong induction of pretomanid which likely occurs at the level of CYP3A. In contrast, the mechanism behind the moderate increase in moxifloxacin and pretomanid exposures that are observed in rats when the drugs are co-administered as PaMZ is unclear. Enhanced bioavailability is a plausible mechanism for pretomanid but would not explain the increase in exposure for moxifloxacin which is well absorbed in the absence of other medications. Whether linearity is compromised at the doses studied, or this reflects a species-specific interaction is unclear.

Excretion

In healthy volunteers, approximately 53% of the total dose is recovered in the urine, of which very little is unchanged drug (1%). Nearly 38% of the total dose is recovered in feces. The elimination half-life is ~17 hours regardless of food conditions. Data are not currently available for individuals with impaired renal function, but such studies have been requested by the FDA and are in progress. A steady state dose escalation study of pretomanid identified a relationship between trough concentrations of the drug and increased circulating serum creatinine levels (R2= 0.59) with a subsequent decline after discontinuation of the drug. In contrast, there was no consistent change in blood urea nitrogen levels.61 The authors subsequently attempted to explore the mechanism behind these findings, specifically whether there were corresponding increases in protein catabolism or reductions in renal function.71 The follow-up study suggests that these changes are likely the result of inhibition of creatinine secretion at the level of the renal proximal tubule.

Transport

In considering transport, pretomanid does not appear to be a substrate for OAT1, OAT3, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP or P-gp based on in vitro transporter assays in MDCK-II cells and MDCK_MDR1 cells.66 Inhibition by pretomanid of the aforementioned transporters was also evaluated in vitro. At clinically relevant concentrations, pretomanid inhibits the renal tubular uptake transporter OAT3 which could reduce the clearance of substrate drugs (eg, antibiotics, antivirals, H2-receptor antagonists, diuretics, NSAIDs, statins, uricosurics, and methotrexate). Inhibition of MATE2-K at clinically relevant concentrations is less likely while no inhibition is expected for OAT1, OCT1, OCT2, OAT1B1, OATP1B3, BCRP, BSEP, P-gp, and MATE1 (TB Alliance, personal communication data).66

Toxicology

The majority of data regarding potential toxic effects of pretomanid comes from in vitro and preclinical studies. No mutagenic or clastogenic effects of pretomanid were detected in Ames assays (5000 μg/plate), Chinese hamster ovary cell assays (up to 1000 μg/mL), in vitro mouse lymphoma assays (up to 500 μg/mL), and in vivo mouse micronucleus assays (up to 2000 mg/kg/day). However, the hydroxy imidazole metabolite (M50) which accounts for ~6% of the human pretomanid exposure, was positive on Ames testing.66 No significant increase in the incidence of lung tumors, hemangiosarcoma, nonvascular tumors, and other tumors was found after 26-weeks of daily pretomanid dosing in TG.rasH2 mice (TB Alliance, personal communication data). A post-marketing 2-year carcinogenicity study in rats has recently been completed and is under regulatory review at the time of this publication. Long-term safety data in humans are not yet available but will shed light on carcinogenicity and mutagenicity with clinical use of pretomanid.

At exposure most relevant to labeled dosing in humans, organ specific safety signals from animal studies demonstrate the potential for hepatic, ophthalmologic and reproductive toxicity (TB Alliance, personal communication data).66 A dose-dependent increase in liver weight without histopathological findings was seen in non-human primates and the no-observed-adverse-event-level (NOAEL) was set at 1.5x human exposure. Murine studies demonstrated hepatic hypertrophy and limited liver transaminase elevations with NOAEL at 7x human exposure. Mixed ophthalmological findings in non-human primates led to NOAEL of 100 mg/kg/day (~2.6x human exposure). In rats, 20% developed cataracts at various dosing schemes and ultimately the NOAEL was set to 30 mg/kg/day (~1.5x human exposure); however, cataracts were not seen in monkeys at 1–2x human exposure. Neurological findings, eg, seizures and ataxia, were present in short-term high dose studies (eg, 2 weeks at 1000 mg/kg/day) in non-human primates, but rarely present in long-term studies. The NOAEL was set at 50 mg/kg/day (~1.3x human exposure).

QTc prolongation is not expected at labeled dosing. A dose-dependent increase in QTc was observed in non-human primates with NOAEL set at 150 mg/kg (4x human exposure). This finding appears consistent with an in vitro cardiac safety screen (hERG current inhibition) demonstrating an IC50 equivalent to 3x Cmax in plasma at labeled doses. One study used modeling and simulation to evaluate the impact of pretomanid alone and in combination (BPaL) on QTc interval using data from 8 clinical trials submitted in the NDA. Although a positive exposure-response relationship was found, <10 ms increase is expected at maximum plasma concentrations seen with labeled dosing.72

According to initial FDA review documents, the testicular toxicity in monkeys was set to 50 mg/kg;66 however, more recent data from the sponsor report an NOAEL of 100 mg/kg/day (~2.6x human exposure) with no abnormal testicular findings after 9 months of dosing in monkeys. The NOAEL for maternal and embryo-fetal effects in rats was 10 mg/kg and 30 mg/kg, respectively and in rabbits was 10 mg/kg and 60 mg/kg, respectively. In lactating dams treated with a regimen thought to be equivalent to human exposure, a single point estimate of pretomanid revealed a higher concentration in milk (1.6 µg/mL) compared with plasma (1.1 µg/mL). At regimens equivalent to 2–4x human exposure, concentrations in milk were 59–68% of plasma concentrations. These data merit discussions of off-label use in children and pregnant females. No lactation data are yet available in humans and alternative therapy may be considered until more is known.73 The FDA has required a post-marketing human semen study and, once available, data can inform clinical discussions with males of reproductive age.

Shared decision-making regarding treatment of MDR/XR-TB with a pretomanid-containing regimen should involve discussion of the potential pretomanid toxicity based on limited animal data weighed carefully against the risk of untreated TB infection. For pregnant adults specifically, it is important to acknowledge the known adverse maternal and fetal outcomes associated with untreated tuberculosis74 while balancing the unknown teratogenic and developmental effects of pretomanid. Because of the lack of data, the WHO does not currently recommend use of pretomanid in pregnancy.

Efficacy and Safety

For the initial review of the new drug application (NDA), the FDA assessed interim data from the NIX-TB trial for participants who had completed the 6-month post-treatment follow up or died (n=45). The efficacy data in the NDA were updated throughout the review and based primarily on n=81 participants available by an interim data cut-off date. Data from all participants who received pretonamid (n=109) were available prior to full approval.66 The NIX-TB trial (n=109) enrolled participants with XDR-TB (65%) and MDR-TB (35%). Fifty-one percent of the participants were HIV+. In the intention-to-treat (ITT) analysis, favorable outcomes were 90% and 88% at 6 months and 24 months, respectively, and not influenced by sex and HIV status (Table 2).75,76 A recent case study describes the successful treatment of MDR-TB using a lower linezolid dynamic dosing based on an exposure target of 600 mg/d vs 1200 mg/d in combination with pretamonid and bedaquiline.77 Similar regimens are currently being evaluated in the ZeNix trial. Table 3 lists ongoing trials for pretomanid-containing regimens, some of which include pediatric patients. No efficacy data are yet available for these trials at the time of this review.

Table 2

Efficacy of Pretomanid-Containing Regimens

Trial	Regimen	Phenotype	mITT at 6 Months		PP
			Favorable	Unfavorable	Favorable	Unfavorable
NIX-TB^	Pa200 QD, B400 QD x 2 weeks then B200 3x/week, L1200 QD X 30 weeks	XDR (n=71)	63* (90%)	7 (10%)	62 (91%)	6 (9%)
		TI/NR MDR (n=38)	35 (95%)	2(5%)	35 (95%)	2 (5%)
STAND	Pa100 M400 Z1500 X 17 weeks	DS-TB	38 (66.7%)	19 (33.3%)	38 (73.1%)	14 (26.9%)
STAND	Pa200 M400 Z1500 X 17 weeks	DS-TB	46 (75.4%)	15 (24.6%)	46 (80.7%)	11 (19.3%)
STAND	Pa200 M400 Z1500 X 26 weeks	DS-TB	43 (76.8%)	13 (23.2%)	43 (91.5%)	4 (8.5%)
STAND	H75 R150 Z400 E275 X 8 wks; H75 R150 wks 9 to 26	DS-TB	52 (86.7%)	8 (13.3%)	52 (98.1%)	1 (1.9%)
STAND	Pa200 M400 Z1500 X 26 weeks	MDR-TB	10 (90.9%)	1 (9.1%)	10 (100.0%)	0 (0.0%)

Notes: *The following categorical variables had no appreciate impact on mITT: HIV status, linezolid regimen (600 mg BID or 1200 QD), age (above or below median), gender, race (black vs white/other), cavitation, TTP at baseline from MGIT (above or below median). ^NIX-TB- Two exclusions in mITT resulting in total n=107 (non-TB related death in follow up and lost to follow up after end of treatment). Two additional exclusions in PP resulting in total n=105 (one inadequate amount of drug and one withdrawn not for treatment failure).

Abbreviations: mITT, modified intention to treat; PP, per protocol.

Table 3

Ongoing Clinical Trials of Pretomanid-Containing Regimens for TB

Trial	Design	Drug Regimens	Comparator	Population	Primary Outcome(s)	Expected/Reported Completion Date	Clinical Trial
ZeNix	Multicenter, partially-blinded (Z only), randomized, Phase III	BPaL1200 x 26 wkBPaL1200 x 9 wkBPaL600 x 26 wkBPaL600 x 9 wk	n/a	MDR-TB, XDR-TB or pre-XDR-TB, target enrollment n=180; ≥14 yrs	Incidence of bacteriologic failure or relapse or clinical failure through follow up until 26 weeks after the end of treatment	12/2021	NCT03086486
SimpliciTB	Multicenter, open-label, partially randomized, phase IIc	BPaMZ	HRZE or HR	DS-TB and DR-TB, n=455; ≥18 yrs	Time to culture conversion to negative status over 8 weeks	4/2020	NCT03338621
TB-PRACTECAL	Multicenter, open label, multi-arm, randomized, controlled, Phase II–III trial	BPaML or BPaCL or BPaL	Locally accepted SOC	MDR-TB, target enrollment n=630; ≥15 yrs	Stage 1: % culture conversion in liquid media at 8 wksStage 1: %treatment discontinuation for any reasonStage 2: % unfavorable outcome	Early 2023	NCT02589782

Abbreviations: B, bedaquiline; C, clofazimine; DR-TB, drug resistant tuberculosis; DS-TB, drug susceptible tuberculosis; E, ethambutol; H, isoniazid; L, linezolid; M, moxifloxacin; MDR-TB, multidrug resistant tuberculosis; Pa, pretomanid; R, rifampicin; SOC, standard of care; XDR-TB, extensively resistant tuberculosis; Z, pyrazinamide.

In the completed NIX-TB trial, all 109 participants (100%) experienced at least 1 treatment emergent adverse event (TEAE), nearly all of which were considered related to study drug (99%). In 19 subjects (17.4%) 36 serious TEAEs were reported, with infection being most prominent (11 events). One event each of mild optic neuropathy and elevated transaminases was reported.75 No grade ≥3 ophthalmic TAEs were reported and there was no evidence of cataracts detected by slit lamp examinations associated with pretomanid.75 All surviving participants were able to complete the full course of therapy with some interruptions due to adverse events, and no adverse-event related withdrawal. The STAND trial, which evaluated pretomanid, moxifloxacin, and pyrazinamide compared with standard treatment (HRZE), found more than a 2-fold higher rate in gastrointestinal (nausea, vomiting, diarrhea) and pulmonary (pleuritic pain, hemoptysis, URI) adverse events. Transaminase elevations along with the elevation of other LFTs were seen with moderate frequency among the non-serious AEs but at a rate comparable to HRZE. Three hepatotoxicity associated deaths initially prompted study suspension, but the study was allowed to resume after independent review by the drug safety monitoring committee. Overall, a higher rate of unfavorable outcomes for the primary measure compared with HRZE and failed non-inferiority criterion prompted early termination of the STAND trial.78

Safety data from ongoing trials (Table 3) are not yet publicly available. A recent Phase 2b study in drug-susceptible or rifampin-resistant TB found that both pretomanid regimens outperformed standard therapy (HRZE) in the primary outcome, but also had higher rates of discontinuation due to adverse events (8–10% vs 3%). Serious adverse events occurred in two participants (3%) receiving BloadPaZ and one participant (2%) receiving HRZE. Preliminary efficacy and adverse event data from this Phase 2b study argue for continued study of B200PaZ in drug susceptible TB, particularly given its shorter duration of therapy and simplified dosing scheme (once daily).79

When the regimens are broadly combined and treatment-emergent non-serious adverse events are evaluated against a standard HRZE regimen (Table 4), neurologic and hepatic disturbances appeared to be more prevalent in the pretomanid containing regimens with arthralgias and gastrointestinal events more prevalent in the moxifloxacin containing regimens. Pretomanid alone (n=411) results in minimal liver toxicity with only 2.2% of individuals experiencing ALT or AST >5 x ULN, or total bilirubin >2 x ULN compared with 5.6–11.7% in pretomanid containing combination regimens and 6.5% in control or placebo regimens. These safety data suggest that liver toxicity is largely related to other anti-TB medications.80 Ascribing clinical trial related ADRs to pretomanid is confounded by the lack of long-term administration data for pretomanid alone. Headache may be attributed to pretomanid as it occurred more frequently in patients receiving pretomanid alone than control (31.5% vs 22.9%) and occurred more frequently at higher pretomanid doses (45.6% in those receiving >200 mg) (TB Alliance, personal communication data). No participants experienced arthralgia, hyperuricemia, hepatic enzyme elevations, hyperuricemia, hyperglycemia, somnolence, anemia, pruritic rash, photophobia, visual acuity disturbance, hematuria, proteinuria, breast disorders or death when taking pretomanid alone (n=122). Nausea occurred in 4.1% of pretomanid only group vs 6.1% in HRZE control group (TB Alliance, personal communication data). For individuals receiving the BPaL regimen, expert consensus suggests that hepatic enzyme elevations, lens disorders, dermatitis, GI upset, and severe cutaneous adverse reactions are more likely to be attributed to pretomanid rather than the other regimen components.

Table 4

Treatment Emergent Adverse Events for Various Regimens

Regimen	PaMZ n=148	BPaZ n=119	BPaMZ n=60	BPaL n=109	HRZE n=120
Trial				NIX-TB
Nausea	30 (20.3%)	4 (3.4%)	5 (8.3%)	40 (36.7%)	8 (6.7%)
Vomiting	18 (12.2%)	5 (4.2%)	7 (11.7%)	37 (33.9%)	11 (9.2%)
Diarrhea	10 (6.8%)	4 (3.4%)	3 (5%)	11 (10.1%)	3 (2.5%)
Abdominal pain/dyspepsia	9 (6.1%)			37 (34%)	3 (2.5%)
Decreased appetite				24 (22.0%)
Abnormal weight loss				11 (10.1%)
Liver disorder	33 (22.3%)				9 (7.5%)
Enzyme abnormality	7 (4.7%)				4 (3.3%)
ALT increased		8 (6.7%)	2 (3.3%)	10 (9.2%)	2 (1.7%)
AST increased		6 (5%)	3 (5%)	9 (8.3%)	3 (2.5%)
Amylase increased			10 (16.7%)		1 (0.8%)
GGT increased		2 (1.7%)	6 (10%)	19 (17.4%)
Anemia		5 (4.2%)	1 (1.7%)	40 (36.7%)
Leukocytosis	9 (6.1%)				3 (2.5%)
Hyperkalemia or hyponatremia	13 (8.8%)				8 (6.7%)
Glucose abnormality	9 (6.1%) - hyper			12 (11%)-hypo	3 (2.5%)- hyper
Hypoalbuminemia	6 (4.1%)				5 (4.2%)
Hyperuricemia	42 (28.4%)	28 (23.5%)	27 (45%)		26 (21.7%)
Dizziness	15 (10.1%)	4 (3.4%)	1 (1.7%)		5 (4.2%)
Headache	14 (9.5%)			30 (27.5%)	2 (1.7%)
Peripheral sensory neuropathy*				76 (69.7%)
Myalgia		7 (5.9%)	3 (5%)		1 (0.8%)
Arthralgia	38 (25.7%)	15 (12.6%)	13 (21.7%)		17 (14.2%)
Extremity or back pain		2 (1.7%)	4 (6.7%)	13 (11.9%)
Acne				17 (15.6%)
Rash		3 (2.5%)	1 (1.7%)	17 (15.6%)	2 (1.7%)
Pruritus generalized		8 (6.7%)	2 (3.3%)		8 (6.7%)
Pruritis	8 (5.4%)	5 (4.2%)	2 (3.3%)	16 (14.7%)	8 (6.7%)
Hemoptysis		4 (3.4%)	6 (10%)	14 (12.8%)
Pleuritic/non-cardiac chest pain			6 (10%)	14 (12.8%)
UTI		2 (1.7%)	4 (6.7%)		2 (1.7%)

Notes: *Peripheral sensory neuropathy includes related codes (eg, neuropathy peripheral, paresthesia, hypoesthesia, peripheral motor neuropathy, burning sensation, hyporeflexia, peripheral sensorimotor neuropathy).

Special Populations

Current WHO recommendations highlight several special populations that deserve careful consideration before pretomanid use. No data are yet available for pretomanid use in children <14 years old, pregnant or lactating women, and medications with more established safety profiles are recommended for use at this time. Breastfeeding is not recommended when taking BPaL. For individuals living with HIV, concomitant antiretroviral therapy should be assessed and efavirenz avoided if possible due to reduced pretomanid exposure. Those taking zidovudine along with the BPaL regimen are at additive risk for peripheral nerve toxicity and myelosuppression from linezolid (rather than pretomanid). Although no data currently exist for pretomanid use in extrapulmonary TB, treatment recommendations are unchanged for individuals with extrapulmonary manifestation of MDR-TB, including TB meningitis. Finally, for individuals with life-threatening extensive drug resistant TB that prevents the application of WHO guideline-based treatment, BPaL may be considered “as a last resort under prevailing ethical standards.”81

Conclusion

Drug resistant MTB strains are difficult to treat, continue to emerge, and threaten global progress in combatting TB.81 The global clinical development pipeline for new anti-TB medicines has less than a dozen new drugs at the early stages of research.82 Since drug development is known to have particularly high attrition rates, only a few of these candidates may reach the market. This status quo and the fact that there were only three new medicines developed for TB treatment in the last 70 years make every emerging anti-TB medicine an important and valuable asset.

Following bedaquiline and delamanid, pretomanid is the third recently approved medicinal agent for use in TB patients as part of the regimen also including bedaquiline and linezolid (BPaL). This 6-month regimen brings a new perspective of shortening treatment for drug-resistant TB and a shift from the currently recommended lengthy and difficult to tolerate and adhere to regimens, that usually last 9 to 20 months, to ones that are shorter and easier to implement. The BPaL regimen is conditionally recommended by WHO to be used under operational research framework that precludes its wider, programmatic use.81 However, the advent of the new medicine – pretomanid, as part of the BPaL regimen and the new guidance from WHO, have already stimulated a massive number of research studies that promise to bring additional evidence that may support broader and stronger recommendations on its use. Additionally, evaluation of cost-effectiveness of the BPaL is ongoing.83

In summary, pretomanid is part of a novel multi-drug regimen for MDR/XR-TB that allows for a shorter duration of therapy. Using shared decision making, counseling regarding benefits and risks may include the possibility of infertility through alterations in spermatogenesis and lack of safety and toxicology data in pregnant patients and breastfed infants. Additional forthcoming data will improve our understanding of the safety, efficacy, and use of pretomanid in TB.